Pharmacokinetic–pharmacodynamic modeling to support doripenem dose regimen optimization for critically ill patients
- 30 April 2009
- journal article
- Published by Elsevier BV in Diagnostic Microbiology and Infectious Disease
- Vol. 63 (4), 409-414
- https://doi.org/10.1016/j.diagmicrobio.2009.01.027
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- In Vitro Activity of Doripenem, a Carbapenem for the Treatment of Challenging Infections Caused by Gram-Negative Bacteria, against Recent Clinical Isolates from the United StatesAntimicrobial Agents and Chemotherapy, 2008
- Bad Bugs Need Drugs: An Update on the Development Pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of AmericaClinical Infectious Diseases, 2006
- Antimicrobial activity of doripenem (S-4661): a global surveillance report (2003)Clinical Microbiology & Infection, 2005
- Use of Pharmacokinetic-Pharmacodynamic Target Attainment Analyses To Support Phase 2 and 3 Dosing Strategies for DoripenemAntimicrobial Agents and Chemotherapy, 2005
- Comparative activity of doripenem and three other carbapenems tested against Gram-negative bacilli with various β-lactamase resistance mechanismsDiagnostic Microbiology and Infectious Disease, 2005
- Doripenem (S-4661), a novel carbapenem: comparative activity against contemporary pathogens including bactericidal action and preliminary in vitro methods evaluationsJournal of Antimicrobial Chemotherapy, 2004
- In Vitro Antimicrobial Activity of Doripenem, a New CarbapenemAntimicrobial Agents and Chemotherapy, 2004
- Comparative in vitro Activity of S-4661, a New Parenteral Carbapenem, and Other Antimicrobial Agents against Respiratory PathogensChemotherapy, 2000
- In Vitro and In Vivo Antibacterial Activities of S-4661, a New CarbapenemAntimicrobial Agents and Chemotherapy, 1998